company background image
MTEM

Molecular TemplatesNasdaqGS:MTEM Stock Report

Market Cap

US$341.3m

7D

-5.1%

1Y

-38.0%

Updated

21 Oct, 2021

Data

Company Financials +
MTEM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MTEM Overview

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Molecular Templates
Historical stock prices
Current Share PriceUS$6.08
52 Week HighUS$5.70
52 Week LowUS$15.19
Beta1.15
1 Month Change-7.03%
3 Month Change-14.25%
1 Year Change-37.96%
3 Year Change45.11%
5 Year Changen/a
Change since IPO1.33%

Recent News & Updates

Sep 22
Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?

Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Aug 15
News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts

News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts

Molecular Templates, Inc. ( NASDAQ:MTEM ) shareholders will have a reason to smile today, with the analysts making...

Shareholder Returns

MTEMUS BiotechsUS Market
7D-5.1%1.1%3.8%
1Y-38.0%17.8%31.5%

Return vs Industry: MTEM underperformed the US Biotechs industry which returned 17.8% over the past year.

Return vs Market: MTEM underperformed the US Market which returned 31.5% over the past year.

Price Volatility

Is MTEM's price volatile compared to industry and market?
MTEM volatility
MTEM Beta1.15
Industry Beta0.98
Market Beta1

Stable Share Price: MTEM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: MTEM's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a254Eric Pomahttps://www.mtem.com

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company’s lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin’s lymphoma.

Molecular Templates Fundamentals Summary

How do Molecular Templates's earnings and revenue compare to its market cap?
MTEM fundamental statistics
Market CapUS$341.35m
Earnings (TTM)-US$94.05m
Revenue (TTM)US$26.15m

13.1x

P/S Ratio

-3.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MTEM income statement (TTM)
RevenueUS$26.15m
Cost of RevenueUS$84.37m
Gross Profit-US$58.22m
ExpensesUS$35.83m
Earnings-US$94.05m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.68
Gross Margin-222.64%
Net Profit Margin-359.66%
Debt/Equity Ratio36.0%

How did MTEM perform over the long term?

See historical performance and comparison

Valuation

Is Molecular Templates undervalued compared to its fair value and its price relative to the market?

3.5x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MTEM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MTEM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MTEM is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MTEM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MTEM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MTEM is overvalued based on its PB Ratio (3.5x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Molecular Templates forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-4.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MTEM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MTEM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MTEM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MTEM's revenue (24% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: MTEM's revenue (24% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MTEM is forecast to be unprofitable in 3 years.


Past Performance

How has Molecular Templates performed over the past 5 years?

-45.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MTEM is currently unprofitable.

Growing Profit Margin: MTEM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MTEM is unprofitable, and losses have increased over the past 5 years at a rate of 45.7% per year.

Accelerating Growth: Unable to compare MTEM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MTEM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: MTEM has a negative Return on Equity (-96.56%), as it is currently unprofitable.


Financial Health

How is Molecular Templates's financial position?


Financial Position Analysis

Short Term Liabilities: MTEM's short term assets ($205.3M) exceed its short term liabilities ($44.7M).

Long Term Liabilities: MTEM's short term assets ($205.3M) exceed its long term liabilities ($102.7M).


Debt to Equity History and Analysis

Debt Level: MTEM's debt to equity ratio (36%) is considered satisfactory.

Reducing Debt: MTEM had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MTEM has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: MTEM has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 35.6% each year.


Dividend

What is Molecular Templates's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MTEM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MTEM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MTEM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MTEM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MTEM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Eric Poma (49 yo)

12.75yrs

Tenure

US$4,609,278

Compensation

Dr. Eric E. Poma, Ph D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as its President. Dr. Poma founded Private Molecular in February 2009...


CEO Compensation Analysis

Compensation vs Market: Eric's total compensation ($USD4.61M) is above average for companies of similar size in the US market ($USD1.68M).

Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MTEM's management team is considered experienced (3.9 years average tenure).


Board Members

Experienced Board: MTEM's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.


Top Shareholders

Company Information

Molecular Templates, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Molecular Templates, Inc.
  • Ticker: MTEM
  • Exchange: NasdaqGS
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$341.346m
  • Shares outstanding: 56.14m
  • Website: https://www.mtem.com

Number of Employees


Location

  • Molecular Templates, Inc.
  • 9301 Amberglen Boulevard
  • Suite 100
  • Austin
  • Texas
  • 78729
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 23:02
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.